Refixia Novo Nordisk A/S · Authorised · authorised 2 Jun 2017 · ATC B02BD04
Therapeutic indication (EMA)
Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency). Refixia can be used for all age groups.
Active substance
Nonacog beta pegol
- SFDA 3
- EMA 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Refixia | 500 IU | Powder and solvent for solution for injection · Intravenous use | 1 Pre-filled syringe | SAR 3052.55 | Biological · Prescription | NOVO NORDISK | Valid |
| Refixia | 1000 IU | Powder and solvent for solution for injection · Intravenous use | 1 Pre-filled syringe | SAR 6105.70 | Biological · Prescription | NOVO NORDISK | Valid |
| Refixia | 2000 IU | Powder and solvent for solution for injection · Intravenous use | 1 Pre-filled syringe | SAR 12211.95 | Biological · Prescription | NOVO NORDISK | Valid |
EMA European Union — centrally authorised medicines
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.